Ultragenyx Pharmaceutical Quarterly Balance Sheet
NASDAQ: RAREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ultragenyx Pharmaceutical financial position
As of Jun 30, 2026, Ultragenyx Pharmaceutical reported total assets of $1.26 billion, down 3.2% from a year earlier against total liabilities of $1.55 billion. Shareholders' equity was negative at -$291.0 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $125.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 1.73, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Ultragenyx Pharmaceutical balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 125.00M | 175.00M | 421.00M | 202.51M | 176.00M | 127.00M | 174.00M | 150.62M | 480.69M | 112.25M | 214.00M | 72.58M |
| Short-Term Investments | 167.00M | 238.00M | 259.00M | 222.74M | 311.28M | 367.38M | 436.00M | 470.99M | 283.13M | 299.83M | 363.63M | 369.52M |
| Receivables | 200.00M | 121.00M | 158.00M | 112.54M | 124.46M | 98.84M | 122.00M | 93.30M | 105.98M | 100.25M | 73.39M | 79.26M |
| Inventory | 59.00M | 55.00M | 52.00M | 52.20M | 46.50M | 46.03M | 45.00M | 43.33M | 40.14M | 35.91M | 33.97M | 31.80M |
| Total Current Assets | 606.00M | 657.00M | 951.00M | 643.21M | 719.79M | 699.15M | 817.00M | 799.61M | 964.64M | 595.97M | 732.18M | 599.19M |
| Property, Plant & Equipment | 235.00M | 239.00M | 244.00M | 249.96M | 255.76M | 260.91M | 266.00M | 272.45M | 278.71M | 285.11M | 290.57M | 296.81M |
| Goodwill | 44.00M | 44.00M | 44.00M | 44.41M | 44.41M | 44.41M | 44.00M | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M |
| Intangible Assets | 172.00M | 174.00M | 176.00M | 172.94M | 174.73M | 176.52M | 178.00M | 164.94M | 166.24M | 165.04M | 166.27M | 157.30M |
| Long-Term Investments | 144.00M | 121.00M | 57.00M | 22.07M | 51.45M | 68.56M | 135.00M | 203.09M | 110.67M | 156.58M | 199.90M | 82.07M |
| Total Assets | 1.26B | 1.30B | 1.53B | 1.19B | 1.31B | 1.31B | 1.50B | 1.54B | 1.62B | 1.31B | 1.49B | 1.24B |
| Accounts Payable | 39.00M | 42.00M | 31.00M | 40.57M | 34.24M | 47.45M | 39.00M | 35.99M | 59.81M | 40.97M | 42.11M | 33.36M |
| Total Current Liabilities | 351.00M | 325.00M | 384.00M | 340.02M | 293.24M | 291.67M | 344.00M | 285.01M | 272.87M | 245.57M | 280.44M | 253.98M |
| Total Liabilities | 1.55B | 1.52B | 1.60B | 1.17B | 1.15B | 1.16B | 1.24B | 1.18B | 1.19B | 1.17B | 1.22B | 1.21B |
| Shareholders' Equity | -291.00M | -236.00M | -80.00M | 9.16M | 151.00M | 144.00M | 255.00M | 346.83M | 432.42M | 140.26M | 275.00M | 31.71M |
| Retained Earnings | -4.81B | -4.72B | -4.53B | -4.40B | -4.22B | -4.11B | -3.96B | -3.82B | -3.69B | -3.56B | -3.39B | -3.26B |
| Net Cash (Debt) | 292.00M | 413.00M | 680.00M | 425.25M | 487.28M | 494.38M | 610.00M | 621.61M | 763.82M | 412.08M | 577.63M | 442.09M |
| Shares Outstanding | 98.60M | 98.30M | 96.60M | 96.44M | 96.35M | 93.90M | 92.50M | 92.30M | 92.14M | 83.09M | 82.32M | 72.17M |
This table shows 12 quarterly periods of Ultragenyx Pharmaceutical's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RARE's reporting calendar. What is a balance sheet?